knowledge -WSS

knowledge

author：entertainment 2025-09-06 04:40:46 - browse：68363

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Can medical device makers keep up in the race to treat obesity?

WSS

Timeline: Key moments in fight for gay rights

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Jerome Adams on the need for new antivirals for Covid

At least 13 dead in Texas as scorching temps continue

Bispecific antibodies are next new thing in cancer immunotherapy

Medical leaders decry Supreme Court decision on affirmative action

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

Hollywood unions extend contract negotiations for actors

BioMarin wins approval for gene therapy to treat hemophilia A

Medical leaders decry Supreme Court decision on affirmative action

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In Memoriam: Notable people who died in 2023

As demand for Covid shots wanes, Moderna seeks its next success

Supreme Court strikes down use of affirmative action

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

The thinking behind the controversial eating disorder chatbot Tessa

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Novo: Oral version of Ozempic leads to 15% weight loss

Bispecific antibodies are next new thing in cancer immunotherapy

ChatGPT in medicine: STAT answers readers' burning questions

explore

focus

hotspot

entertainment